Institute of Hematology & Blood Diseases Hospital, China is conducting a study to evaluate the safety and efficacy of daratumumab in the treatment of immune thrombocytopenia in ITP patients who are steroid-refractory or steroid-dependent. Daratumumab, a kind of anti-CD38 antibody, is a new type of monoclonal antibody targeting CD38. The study is open to those with a confirmed diagnosis of ITP who are at least six years of age, and who have failed to respond to corticosteroid therapy (either due to loss of response or a on reliance the drug). Patients should have a history of response to previous ITP standard first-line therapy (glucocorticoids and/or intravenous human immunoglobulin). ITP patients will be excluding from participating if they are allergic, or have had a negative serum reaction, to any anti-CD38 monoclonal antibody or who have received anti-CD38 monoclonal antibody in the past and failed.

China

https://clinicaltrials.gov/study/NCT06838962?cond=Immune%20Thrombocytopenia&aggFilters=status:rec&limit=100&page=1&rank=28

Actively Recruiting